Ikena Oncology

75 articles about Ikena Oncology

• Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

  4/20/2023

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023.

• Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

  4/17/2023

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”) today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

• Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

  3/7/2023

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”) today announced that the Company is presenting preclinical data on its newest program in next-generation MEK-RAF inhibition, IK-595, at the American Association for Cancer Research (AACR) Special Conference: Targeting RAS, taking place this week in both a poster presentation and a plenary session talk.

• Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

  3/6/2023

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR) antagonist, in combination with immune checkpoint inhibitors in patients with advanced urothelial carcinoma who have progressed on or within three months of receiving the last dose of checkpoint inhibitors.

• Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

  2/28/2023

  Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in a Targeted Oncology Panel at the Cowen 43rd Annual Health Care Conference, taking place March 6-8, 2023 in Boston, MA.

• Ikena Oncology Appoints Owen Hughes as Board Chair

  12/19/2022

  Ikena Oncology, Inc. announced that after a successful 4-year tenure as Chairman of the Board of Directors, Ron Renaud will be stepping down from the role to focus on his new position as Managing Director at Bain Capital Life Sciences.

• Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

  11/28/2022

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development candidate in the RAS pathway.

• Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

  11/22/2022

  Ikena Oncology, Inc. today announced that management will present a corporate overview and participate in 1x1 investor meetings at the Piper Sandler 34th Annual Healthcare Conference, taking place November 29-December 1, 2022, in New York, NY.

• Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

  11/10/2022

  Ikena Oncology, Inc. today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

• UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/7/2022

  Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced financial results for the third quarter ended September 30, 2022.

• Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/7/2022

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the third quarter ended September 30, 2022.

• Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

  10/26/2022

  Ikena Oncology, Inc. today announced a poster presentation highlighting preclinical data on the company’s novel TEAD inhibitor, IK-930, at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.

• 

  AstraZeneca, Ikena Team Up Against EGFR-mutated NSCLC - Updated

  10/19/2022

  Ikena Oncology and AstraZeneca have entered into an agreement to evaluate Tagrisso (osimertinib) with Ikena's IK-930 in EGFR-mutated non-small cell lung cancer.

• Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

  10/18/2022

  Ikena Oncology, Inc. today provided a research & development update on the Company’s lead targeted oncology program in TEAD inhibition.

• Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

  10/5/2022

  Ikena Oncology, Inc. announced that two abstracts highlighting the company’s Aryl Hydrocarbon Receptor antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.

• Ikena Oncology to Participate in September 2022 Investor Conferences

  9/6/2022

  Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in two upcoming investor conferences in New York, NY.

• Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

  8/11/2022

  Ikena Oncology, Inc. today announced financial results for the second quarter ended June 30, 2022.

• Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

  6/22/2022

  Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM).

• Ikena Oncology to Participate in Spring 2022 Investor Conferences

  5/18/2022

  Ikena Oncology, Inc. announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.

• Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  5/12/2022

  Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced financial results for the first quarter ended March 31, 2022.